From the Journals

Adherence to antireflux lifestyle factors shows benefit in women


 

FROM JAMA INTERNAL MEDICINE

Lifestyle matters

According to Ronnie Fass, MD, medical director of the Digestive Health Center at Case Western Reserve University, Cleveland, “This is the first study to show the incremental effect and thus the benefit of lifestyle factors in reducing the risk of GERD symptoms. While only five lifestyle factors were assessed in this study, potentially others may further decrease the risk for symptoms.”

Dr. Ronnie Fass

Dr. Fass

Dr. Fass suggested that the nature of the data, which was self-reported, and the entirely female patient population, should inform interpretation of the findings.

“While nonerosive reflux disease is relatively more common in women, erosive esophagitis and Barrett’s esophagus are more common in men,” he said. “Furthermore, male gender is associated with more severe GERD and GERD complications.”

Yet Dr. Fass concluded by again emphasizing the merit of the analysis: “This is an important study that further supports the value of certain lifestyle factors in reducing the risk of GERD symptoms,” he said. “What is challenging for practicing physicians is to get patients to follow these lifestyle factors long term.”

The study was funded by the National Institutes of Health and by a Stuart and Suzanne Steele Massachusetts General Hospital Research Scholar Award. The investigators and Dr. Fass disclosed no conflicts of interest.

Pages

Recommended Reading

COVID-19 may alter gut microbiota
Clinician Reviews
Incidence of autoimmune hepatitis may be rising
Clinician Reviews
High cost of pancreatic enzymes a barrier for patients with cancer
Clinician Reviews
Tofacitinib for RA misses the mark in safety study
Clinician Reviews
AGA Clinical Practice Update: Diagnosis and management of immune checkpoint inhibitor enterocolitis and hepatitis
Clinician Reviews
AGA Clinical Practice Update: Bariatric surgery in patients with cirrhosis
Clinician Reviews
Vedolizumab looks safer than anti-TNF drugs in older adults with IBD
Clinician Reviews
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseases
Clinician Reviews
Psychological difficulties persist among patients with IBD
Clinician Reviews
ACG: CRC screening should start at age 45
Clinician Reviews